Clinical trials: Cerebral Disorder
Alzheimer's Disease
Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)
This study is a Phase 2, randomized, placebo-controlled, dose-ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety…
- Trial name
- NCT02615002
- Testing
- Piromelatine
- Where
- 56 sites in United States
- Volunteers
- 371 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Alzheimer Disease, Dementia
Efficacy of Gamification in Enhancing User Engagement
As part of Phase II of the NIH SBIR grant, the study will conduct a randomized controlled clinical trial in which the MapHabit system's gamification is investigated to determine whether the assistive technology facilitates user…
- Conditions
- Alzheimer Disease, Dementia, Gamification, Assistive Technology
- Trial name
- NCT05422339
- Testing
- The MapHabit system (MHS)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- MapHabit, Inc.
Alzheimer Disease (AD)
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
- Trial name
- NCT03518073
- Testing
- Zagotenemab
- Where
- 60 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company
Glioma, Brain Neoplasm
Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
This drug is being developed to treat a type of brain cancer, glioma. This study was designed to determine a safe and well tolerated dose.
- Trial name
- NCT00040573
- Testing
- 131I-TM-601
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- TransMolecular
Concussion, Brain, Mild Traumatic Brain Injury
A Highly Portable Device for Assessment of Mild Traumatic Brain Injury in Deployed and Far-Forward Settings
The purpose of this study is to develop a highly portable, ruggedized diagnostic tool for concussion, EyeBOX Lens (EBLens), that can be utilized in deployed field and far-forward settings.
- Trial name
- NCT05527041
- Testing
- EyeBOX Lens (EBLens)
- Where
- United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Oculogica, Inc.
Alzheimer Disease
Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers.
- Trial name
- NCT03030105
- Testing
- BPN14770, Donepezil, Scopolamine 0.6 MG/ML
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Early Stage Parkinson Disease
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD.
- Trial name
- NCT00335166
- Testing
- Pardaprunox, pramipexole
- Where
- 89 sites in United States, Australia and 16 more
- Volunteers
- 330 people
- Sponsor
- Solvay Pharmaceuticals
Alzheimer Disease, Early Onset
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants…
- Trial name
- NCT07328451
- Testing
- DNL628
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Denali Therapeutics Inc.
Parkinson's Disease
Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease
This study is a multicenter, randomized, double-blind, placebo controlled, parallel group study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in patients with advanced stage Parkinson's disease…
- Trial name
- NCT00134251
- Testing
- SLV308
- Where
- 10 sites in Bulgaria, Malta and 1 more
- Sponsor
- Solvay Pharmaceuticals
Migraine
Acute Treatment Trial in Adult Subjects With Migraines
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
- Trial name
- NCT03872453
- Testing
- Zavegepant, Intranasal Aptar Pharma Unit Dose System
- Where
- 82 sites in United States
- Volunteers
- 2,154 people
- Sponsor
- Pfizer
Antidiuretic Hormone, Inappropriate Secretion
Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH
The purpose of this study is to confirm the safety of tolvaptan in patients with hyponatremia in syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Japan
- Trial name
- NCT04790175
- Testing
- Tolvaptan (SAMSCA)
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Traumatic Brain Injury
Evaluation of Biomarkers of Traumatic Brain Injury
The primary objective of this study is to evaluate the utility of the Banyan UCH-L1/GFAP Detection Assay as an aid in the evaluation of suspected traumatic brain injury (Glasgow Coma Scale score 9-15) in conjunction with other…
- Trial name
- ALERT-TBI (NCT01426919)
- Testing
- Head CT scan and blood draw within 12 hours of injury
- Where
- 24 sites in United States, Germany and 1 more
- Volunteers
- 2,011 people
- Sponsor
- Banyan Biomarkers, Inc
Phenylketonurias
Evaluation of PKU Sphere
A prospective, open-label study of PKU Sphere in patients with PKU following a phenylalanine restricted therapeutic diet.
- Trial name
- NCT03419819
- Testing
- PKU Sphere
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Vitaflo International, Ltd
Parkinson's Disease
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
This is a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and pharmacokinetics (PK) of ND0612 in Parkinson's disease (PD) patients on an optimized oral levodopa (LD) regimen and experiencing ≥2…
- Trial name
- ND0612/003 (NCT01883505)
- Testing
- ND0612, Entacapone
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- NeuroDerm Ltd.
Alzheimer's Disease
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).
- Trial name
- ExpeditionPRO (NCT02760602)
- Testing
- Solanezumab
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
This study will investigate safety, tolerability and pharmacokinetics of ABT-126 in up to 20 male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's disease on stable doses of…
- Trial name
- NCT01482845
- Testing
- ABT-126
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Abbott
Ischemic Stroke
Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
To determine the revascularization rate of the CE-marked Trevo device in large vessel occlusions in ischemic stroke patients. Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro…
- Trial name
- TREVO (NCT01088672)
- Testing
- Mechanical Thrombectomy
- Where
- 7 sites in Austria, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Stryker Neurovascular
Stroke
A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial
Current literature has only limited information on the natural history of acute ischemic stroke from large vessel occlusion in a stroke cohort who presents within 8 hours from symptom onset, particularly on 90 day functional…
- Trial name
- FIRST (NCT01092819)
- Testing
- Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies
- Where
- 3 sites in United States, China
- Volunteers
- 150 people
- Sponsor
- Penumbra Inc.
Migraine
Real-world Data Analysis of REN Treatment in Migraine Patients
Data analysis concerning four sets of metrics: A. Per-treatment patterns of REN use as a standalone treatment vs. in combination with medications. B.
- Trial name
- NCT04992897
- Testing
- Remote Electrical Neuromodulation (REN)
- Where
- 2 sites in United States, Israel
- Volunteers
- 12,151 people
- Sponsor
- Theranica
GM1 Gangliosidosis, GM2 Gangliosidosis
Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2
This study is being conducted to better understand the natural course of GM1 gangliosidosis, GM2 gangliosidoses and Gaucher disease Type 2 (GD2).
- Conditions
- GM1 Gangliosidosis, GM2 Gangliosidosis, Gaucher Disease, Type 2, Tay-Sachs Disease
- Trial name
- RETRIEVE (NCT04470713)
- Where
- 17 sites in United States, Belgium and 8 more
- Volunteers
- 226 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.